Conflux

Diagnostic intelligence,
built on evidence

Every pathology report drives critical decisions in a patient's journey. But rising caseloads, expanding panels, and evolving guidelines make it harder than ever to keep up.

Conflux structures your findings, surfaces relevant evidence, and flags possible gaps before sign-out—all within your existing workflow.

Get in touch See Our Capabilities

Increasing complexity, fragmented evidence

Missed biomarkers delay treatment. Inconsistent measurements trigger amendments. Unreported elements lower reimbursement. Pathologists are under pressure amid a fragmented evidence and guideline base—with patient outcomes on the line.

Conflux is a physician-centered AI that closes this gap: structured context, live evidence, and pre-sign-out checks embedded directly in your reporting workflow.

H&E stained tissue with AI cell segmentation overlays

H&E histology · glass & digital labs

Not just another AI layer on top of your work, but context-aware diagnostic intelligence supporting it, built for the rigor and traceability that diagnosis demands.

Introducing Conflux

Real-time evidence for pathology

Conflux fits your existing workflow—live, or on demand:

Ambient Sync

Real-time, as you report. Ambient Sync captures your case from the LIS and delivers live evidence, error checks, and ancillary recommendations, following in real time as you write the report.

Instant Review

After the fact, on demand. Paste a completed report and get evidence search, structured context, and pre-sign-out checks. Proofreading, built into your existing report writing.

Private Beta

Enterprise

Beyond the browser. Conflux embeds directly into your LIS, delivering unparalleled efficiency and evidence-based reporting standards. Get in touch to learn more.

Export
Final Diagnosis
A
Colon, Sigmoid — Polypectomy
Invasive adenocarcinoma, moderately differentiated, pT1.
B
Colon, Ascending — Biopsy
Sessile serrated lesion.
Grade required · CAP protocol
C
Stomach, Body — Biopsy
Gastric adenocarcinoma, intestinal type, mod. diff.
D
Stomach, Antrum — Biopsy
H. pylori gastritis, active.
Eradication status not documented
Ancillary Workup
KRAS G12C Mutation Testing
Invasive colorectal adenocarcinoma. Targeted KRAS G12C testing recommended, identifying eligibility for mutation-specific combination therapy.
If G12C+ · sotorasib + panitumumab NEJM 2023 · CodeBreaK 300
Evidence Search
Mod Pathol 2024 · Multicenter Validation
Tumor budding (Bd3) in pT1 CRC: LNM risk 23% vs <2% for Bd1. Budding grade reclassifies endoscopic cases for surgical management.
1 issue Case SP-24-8821 · 4 parts
Ancillary Workup
Real-time proofreading
Evidence Search

Report wherever you choose. Conflux works alongside your existing workflow.

01

Ambient Sync

Real-time intelligence alongside your LIS

Capture case context from your LIS in real time, with no integrations and no workflow disruption. Evidence, proofreading, and structured context stream live whether you report in the LIS, Word, or any other tool.

File Edit View Results
Laboratory Information System
Case # SP-24-10432
Specimen Colon, Sigmoid
Procedure Polypectomy
Diagnosis
Watching
Conflux
Context Captured Sigmoid colon · polypectomy
Evidence Match WHO 5th ed. tubular adenoma classification
Proofread Check Dysplasia grade not documented
02

Evidence Awareness

Evidence and guidelines, surfaced when they matter

CAP, NCCN, and institutional protocol checks are the baseline. Conflux goes further, surfacing cutting-edge literature that connects findings to emerging therapies, evolving classifications, and diagnostic refinements ahead of the guideline consensus.

Real-time Evidence
Classification Guideline
WHO Classification of Tumours: Digestive System, 5th Ed.
WHO Classification of Tumours Editorial Board (2019)
Tumour Budding in Colorectal Carcinoma — WHO Classification of Tumours: Digestive System
Standardizes budding as Bd1 (0–4 buds), Bd2 (5–9), Bd3 (≥10) per 0.785 mm² hotspot at 20× objective. Bd3 in pT1 CRC associated with >20% lymph node metastasis risk.
Grading Criteria
"Tumour budding should be reported using the three-tier ITBCC system (Bd1/2/3) and included as a mandatory data element in all colorectal resection specimens."
Budding grade directly determines whether polypectomy is curative or surgical re-excision is required.
Article Recommendation
New England Journal of Medicine
(André, T et al. 2020)
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer (KEYNOTE-177)
Phase III, n=307 MSI-H/dMMR mCRC. First-line pembrolizumab vs. chemotherapy: mPFS 16.5 vs 8.2 months (HR 0.60, p=0.0002). ORR 43.8% vs 33.1%. FDA-approved first-line for MSI-H/dMMR mCRC.
MMR Status Utility
"Pembrolizumab significantly prolonged progression-free survival versus chemotherapy as first-line treatment for patients with MSI-H/dMMR metastatic colorectal cancer."
MMR IHC status documented at polypectomy directly determines eligibility for first-line immunotherapy.
03

Clinical Context

Structured context when you need it

Fixed templates force you to work around someone else's schema. Conflux surfaces exactly what you need, when you need it: slide identification, clinical history, compliance data, or research criteria, extracted on demand from your available clinical sources, with full traceability.

Real-time Extraction
Case Materials
Gross Description
Received fresh, labeled "left breast, mastectomy" is a 385g mastectomy specimen measuring 18 × 15 × 4 cm. The skin ellipse measures 12 × 6 cm and contains a central nipple-areolar complex. Serial sectioning reveals a firm, stellate, tan-white mass measuring 2.3 × 1.8 × 1.5 cm located at 10 o'clock, 3 cm from the nipple; closest margin 4 mm (posterior).
Clinical Notes
Patient completed neoadjuvant chemotherapy, 4 cycles AC-T, with partial clinical response. Pre-operative imaging showed residual mass at 10 o'clock with clear lateral and medial margins.
Extraction

Click any card to reveal its source

04

Report Proofreading

Catch errors before sign-out, not after.

Real-time monitoring flags potential inconsistencies, missing fields, contradictory findings, and pending ancillaries before the report leaves the department.

Pre-Sign-Out Proofreader
Pathology Report
Diagnosis: Invasive ductal carcinoma, Nottingham grade 2, ypT1.
Tumor Size: 2.3 cm
Margins: Negative, closest 2 mm
LVI: Not identified
Biomarkers: ER 90%+, PR 45%+, HER2 1+
Response: Not documented
Sign Out
Live Checks 0 issues
Scanning report…
STAGING CONFLICT
ypT1 staging conflicts with measured tumor size
Tumor measures 2.3 cm (23 mm), exceeding the 20 mm ypT1 ceiling. Reclassify as ypT2.
MISSING FIELD
No pathologic response assessment documented
Clinical history records neoadjuvant chemotherapy prior to resection. Miller-Payne grade or RCB score expected per CAP protocol.
05

Write Mode · Optional

Ready to re-imagine your reporting experience?

Dictate or type and get AI-powered autosuggest, structured extraction, and personalized diagnosis output—all backed by the same evidence layer.

AI-enabled Dictation

🗣️
Listening for dictation...

Reportable Elements

Tumor Type:
Grade:
Size:
Margins:
LVI:

Personalized Diagnosis Output

Conflux's language suggestions adapt over time, learning from each pathologist's reporting style and diagnostic preferences.

Intelligent reporting. Deeper evidence. Better outcomes.

See how Conflux fits your workflow—whether you write in our tool, connect via Screen Sync, or paste reports for on-demand review.